Terray Therapeutics, a biotechnology company integrating scale experimentation and generative AI to improve the speed, cost, and success rate of small molecule drug discovery and development, announced a multi-target collaboration agreement with Bristol Myers Squibb to discover and develop small molecule therapeutics in certain disease areas.
Under the terms of the agreement, Terray will discover and develop small molecule compounds against a set of targets nominated by Bristol Myers Squibb using the Terray tNova platform, with Bristol Myers Squibb subsequently assuming responsibility for development and commercialization. Terray will receive an upfront payment and is eligible to receive milestone payments associated with the achievement of preclinical, clinical, and sales milestones as well as tiered royalties on net sales of products commercialized by Bristol Myers Squibb in connection with the collaboration.
“We’re proud to strategically partner with Bristol Myers Squibb,” said Jacob Berlin, Ph.D., Chief Executive Officer, Terray Therapeutics. “This agreement combines the scale, precision, and speed of our platform with the breadth and expertise of our collaborators at Bristol Myers Squibb to find new small molecule therapeutics.”
Terray’s platform is built for generative AI-driven drug discovery, integrating chemical experimentation and computation. Everything the company does is grounded in an iterative approach, producing massive amounts of precise, purpose-built data that enables generative optimization of small molecules—all in service of finding the right molecules to solve complex problems in drug discovery.
Terray is a biotechnology company with the technology, data, and mindset to radically change the way we discover and develop small molecule therapeutics. The company explores molecules and targets with a sophisticated integration of ultra-high throughput experimentation, generative AI, biology, medicinal chemistry, automation, and nanotechnology. Terray’s platform uniquely blends experimentation and computation to deliver on the promise of generative AI for small molecule discovery—finding solutions to the toughest therapeutic challenges.
SOURCE: PRNewswire